Gram-negative bacteria are a serious global health threat due to their resistance to multiple antibiotics, making infections hard to treat. To combat this, the NIH has granted $3.96 million to Vincent Tam from the UH College of Pharmacy to develop more effective combination therapies. Tam plans to design a monitoring device and algorithm to guide therapy design. Gram-negative infections are difficult to fight due to bacteria’s protective capsules preventing white blood cells from ingesting them. Tam aims to identify useful antibiotic combinations and validate them with clinical outcomes. The model could be applied to other pathogens and antimicrobial agents. Co-investigators include experts from UH, Houston Methodist Hospital, and Research Institute.
Source link
NIH awards $3.96 million to develop combination therapies for superbugs
